Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
If you were developing a new antibiotic with a novel MoA, one that covers most GPC, most GNR, most anaerobes and atypicals, including many MDR pathogens like MRSA, enterococci (both E. faecalis and E. faecium), and one that has also activity against rickettsiae and bioterrorism agents, you would consider it a Continue reading Nominating Thiamphenicol for IDSA’s 10 x ’20 Campaign
When antibiotics change hands, it can be a good thing. Small companies are often desperate to attract a partner with ‘deep pockets’ to help them finance an expensive late phase development but often have to give up control once the honeymoon period is over. Such transitions can bring delays because new Continue reading The Circuitous Route to Phase 3: Another Chapter in the Fitful Development of PTK-0796
SVR rates in recent DAA combination trials are really impressive. Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies. This begs the question: is there still room for improvement? Why Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?